Cuban health authorities have granted full regulatory approval to Nasalferon, an innovative nasal spray treatment, following conclusive evidence from Phase III clinical trials demonstrating its effectiveness against respiratory illnesses. The breakthrough medication, developed by Cuba’s Center for Genetic Engineering and Biotechnology (CIGB), represents a significant advancement in accessible antiviral therapy.
The comprehensive clinical research, conducted throughout 2025 across multiple healthcare facilities in Old Havana, yielded compelling results regarding the treatment’s protocol adherence and therapeutic performance. Trial data confirmed Nasalferon’s capacity to effectively manage and completely resolve symptoms associated with respiratory infections while maintaining an excellent safety profile.
Nasalferon utilizes recombinant human alpha 2b interferon as its active pharmaceutical component, a well-established molecule with proven efficacy across various therapeutic applications and pharmaceutical formulations. The product had previously received conditional authorization specifically for SARS-CoV-2 infection prophylaxis during the COVID-19 pandemic. This latest approval significantly expands its indicated use to encompass general acute respiratory infections.
With formal regulatory clearance now obtained, the medication is being distributed through community pharmacies nationwide, available to patients with appropriate medical prescriptions. The Cuban Ministry of Health has established a retail price point of 172.50 Cuban Pesos (CUP) for each 2 milliliter bottle.
Looking toward future applications, CIGB’s research team is planning additional clinical studies to evaluate Nasalferon’s safety and efficacy in pediatric populations. This developmental pathway aims to extend the therapeutic benefits to younger patients once appropriate data collection and analysis are complete. Supported by stable manufacturing capabilities within Cuba’s robust biotechnology sector, Nasalferon stands positioned to become a mainstream therapeutic option for respiratory conditions among the Cuban population.